# Overview of the cardiovascular effects of tadalafil

DOI: 10.1016/s1520-765x(02)90050-7
European Heart Journal Supplements, 2002, 4, H32-H47.

| # | Paper | IF | Citations |
|---|---|---|---|
| 68 | Erectile dysfunction in the cardiac patient. *Current Urology Reports*, **2003**, 4, 466-71 | 2.9 | 16 |
| 67 | Tadalafil in the treatment of erectile dysfunction. *Current Urology Reports*, **2003**, 4, 472-8 | 2.9 | 13 |
| 66 | Cardiovascular effects of tadalafil. *American Journal of Cardiology*, **2003**, 92, 37M-46M | 3 | 98 |
| 65 | Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. *American Journal of Cardiology*, **2003**, 92, 47M-57M | 3 | 85 |
| 64 | Tadalafil: a new treatment for erectile dysfunction. *BJU International*, **2003**, 91, 466-8 | 5.6 | 6 |
| 63 | Erectile dysfunction in the cardiac patient: how common and should we treat?. *Journal of Urology*, **2003**, 170, S46-50; discussion S50 | 2.5 | 156 |
| 62 | Time course of the interaction between tadalafil and nitrates. *Journal of the American College of Cardiology*, **2003**, 42, 1855-60 | 15.1 | 138 |
| 61 | New achievements and pharmacotherapeutic approaches to impotence in the elderly. *Aging Clinical and Experimental Research*, **2003**, 15, 222-33 | 4.8 | 2 |
| 60 | Tadalafil: A Comprehensive Update. **2004**, 2, 225-246 | | |
| 59 | Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. *Journal of Pharmacy Practice*, **2004**, 17, 239-250 | 1.3 | 1 |
| 58 | The efficacy and safety of tadalafil: an update. *BJU International*, **2004**, 93, 1276-81 | 5.6 | 158 |
| 57 | Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. *Journal of Sexual Medicine*, **2004**, 1, 292-300 | 1.1 | 95 |
| 56 | Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. *Journal of Sexual Medicine*, **2004**, 1, 161-7 | 1.1 | 38 |
| 55 | Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. *Clinical Cardiology*, **2004**, 27, I20-5 | 3.3 | 22 |
| 54 | Erectile dysfunction in the cardiac patient. *Comprehensive Therapy*, **2004**, 30, 50-4 | | 6 |
| 53 | Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. *Journal of Urology*, **2004**, 172, 1935-40 | 2.5 | 133 |
| 52 | Reply. *Journal of the American College of Cardiology*, **2004**, 43, 2150-2151 | 15.1 | 2 |

| | | | |
|---|---|---|---|
| 51 | Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. *Urology*, **2004**, 64, 998-1003; discussion 1003-4 | 1.6 | 54 |
| 50 | Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. *Circulation*, **2004**, 110, 3149-55 | 16.7 | 143 |
| 49 | Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. *BJU International*, **2005**, 95 Suppl 4, 19-28 | 5.6 | 39 |
| 48 | Erectile dysfunction in patients with coronary artery disease. *International Journal of Impotence Research*, **2005**, 17, 209-15 | 2.3 | 19 |
| 47 | A case of erectile dysfunction and risk factors for coronary artery disease. *International Journal of Impotence Research*, **2005**, 17 Suppl 1, S7-S11 | 2.3 | 3 |
| 46 | Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). *American Journal of Cardiology*, **2005**, 96, 313-21 | 3 | 216 |
| 45 | Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. *American Journal of Cardiology*, **2005**, 96, 37M-41M | 3 | 36 |
| 44 | Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. *American Journal of Cardiology*, **2005**, 96, 42M-46M | 3 | 63 |
| 43 | Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). *American Journal of Cardiology*, **2005**, 96, 85M-93M | 3 | 99 |
| 42 | The therapeutic dilemma: how to use tadalafil. *Journal of Developmental and Physical Disabilities*, **2005**, 28 Suppl 2, 74-80 | | 36 |
| 41 | Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. *Journal of Sexual Medicine*, **2005**, 2, 415-25; discussion 425-7 | 1.1 | 80 |
| 40 | Therapie der erektilen Dysfunktion. **2005**, 341-352 | | |
| 39 | Tadalafil: a clinical update. *Aging Health*, **2005**, 1, 203-214 | | 3 |
| 38 | Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. *Expert Opinion on Drug Safety*, **2005**, 4, 531-40 | 4.1 | 18 |
| 37 | The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. *Journal of the American College of Cardiology*, **2005**, 46, 678-87 | 15.1 | 27 |
| 36 | Strategies in the oral pharmacotherapy of male erectile dysfunction viewed from bench and bedside (Part I). *The Journal of Mens Health & Gender: the Official Journal of the International Society for Mens Health & Gender*, **2005**, 2, 87-94 | | 2 |
| 35 | Frequently asked questions about tadalafil for treating men with erectile dysfunction. *The Journal of Mens Health & Gender: the Official Journal of the International Society for Mens Health & Gender*, **2005**, 2, 141-157 | | 1 |
| 34 | Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. *Urology*, **2006**, 67, 1199-204 | 1.6 | 54 |

| | | | |
|---|---|---|---|
| 33 | Phosphodiesterase-5 inhibitors and their hemodynamic effects. *Current Hypertension Reports*, **2006**, 8, 345-51 | 4.7 | 23 |
| 32 | Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. *European Urology*, **2006**, 50, 1194-207; discussion 1207 | 10.2 | 74 |
| 31 | The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. *International Journal of Impotence Research*, **2007**, 19, 139-48 | 2.3 | 45 |
| 30 | Erectile dysfunction and hypertension. *International Journal of Impotence Research*, **2007**, 19, 296-302 | 2.3 | 67 |
| 29 | Helping the failing heart and penis. *International Journal of Clinical Practice*, **2007**, 61, 716-8 | 2.9 | |
| 28 | [The basics of phosphodiesterase type 5 (PDE5) inhibition in urology]. *Der Urologe*, **2008**, 47, 1582-7 | | 3 |
| 27 | The cardiovascular safety of tadalafil. *Expert Opinion on Drug Safety*, **2008**, 7, 43-52 | 4.1 | 8 |
| 26 | [Pharmacological, pharmacokinetic, and clinical profile of tadalafil (Cialis)]. *Folia Pharmacologica Japonica*, **2008**, 131, 469-77 | 0 | 1 |
| 25 | Sexual dysfunction: the [prima ballerina[ of hypertension-related quality-of-life complications. *Journal of Hypertension*, **2008**, 26, 2074-84 | 1.9 | 91 |
| 24 | Cardiovascular effects of phosphodiesterase type 5 inhibitors. *Journal of Sexual Medicine*, **2009**, 6, 658-74 | 4.1 | 38 |
| 23 | Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. *Circulation*, **2010**, 122, 88-95 | 16.7 | 78 |
| 22 | Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates. *Current Medical Research and Opinion*, **2010**, 26, 1451-9 | 2.5 | 4 |
| 21 | Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors. *Handbook of Experimental Pharmacology*, **2011**, 307-22 | 3.2 | 8 |
| 20 | Antihypertensive treatment and sexual dysfunction. *Current Hypertension Reports*, **2012**, 14, 285-92 | 4.7 | 65 |
| 19 | Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts. *Current Heart Failure Reports*, **2013**, 10, 26-35 | 2.8 | 14 |
| 18 | Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market. *Sexual Medicine Reviews*, **2018**, 6, 583-594 | 5.6 | 14 |
| 17 | A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects. *Clinical Therapeutics*, **2019**, 41, 1110-1127 | 3.5 | 1 |
| 16 | Positive outcomes of phosphodiesterase type 5 inhibitor on histopathologic and biochemical changes induced by ureteral obstruction. *Revista Da Associação Médica Brasileira*, **2019**, 65, 388-393 | 1.4 | 4 |

| | | | |
|---|---|---|---|
| 15 | Acute pancreatitis induced by Tadalafil: a case report. *Clinical Journal of Gastroenterology*, **2020**, 13, 459-464 | 1.6 | 1 |
| 14 | The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 5 |
| 13 | Update of the position paper on arterial hypertension and erectile dysfunction. *Journal of Hypertension*, **2020**, 38, 1220-1234 | 1.9 | 9 |
| 12 | Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. **2004**, 139-161 | | 1 |
| 11 | Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. *Clinical Interventions in Aging*, **2006**, 1, 439-49 | 4 | 12 |
| 10 | Sexual function in hypertensive patients receiving treatment. *Vascular Health and Risk Management* , **2006**, 2, 447-55 | 4.4 | 31 |
| 9 | Tadalafil: A Comprehensive Update. **2004**, 2, 225-246 | | 1 |
| 8 | Sexual Activity As a Trigger of Myocardial Infarction/Ischemia. **2004**, 251-260 | | |
| 7 | The Hemodynamics of Phosphodiesterase-PDE5 Inhibitors. **2004**, 131-137 | | |
| 6 | Erectile Dysfunction and Cardiovascular Disease. **2007**, 2791-2801 | | |
| 5 | PDE5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Hypertension. **2015**, 185-193 | | |
| 4 | Universal Patient Identifier and Interoperability for Detection of Serious Drug Interactions: Retrospective Study (Preprint). | | |
| 3 | Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. *Current Vascular Pharmacology*, **2021**, 19, 301-312 | 3.3 | 2 |
| 2 | Cardiac Issues Related to Erectile Dysfunction. **2006**, 61-75 | | |
| 1 | Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. *Therapy: Open Access in Clinical Medicine*, **2004**, 1, 185-196 | | |